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Abstract
Background: Precise effects of albuminuria and low estimated glomerular filtration rate (eGFR) on cardiovascular mortality,
all-cause mortality, and renal events in diabetic patients are uncertain.
Materials and Methods: A systematic review was conducted of the literature through MEDLINE, EMBASE, and CINHAL from
1950 to December 2010. Cohort studies of diabetic patients providing adjusted relative risk (RR) of albuminuria and eGFR for
risks of cardiovascular mortality, all-cause mortality, and renal events were selected. Two reviewers screened abstracts and
full papers of each study using standardized protocol.
Results:We identified 31 studies fulfilling the criteria from 6546 abstracts. With regard to the risk of cardiovascular mortality,
microalbuminuria (RR 1.76, 95%CI 1.38–2.25) and macroalbuminuria (RR 2.96 95%CI 2.44–3.60) were significant risk factors
compared to normoalbuminuria. The same trends were seen in microalbuminuria (RR 1.60, 95%CI 1.42–1.81), and
macroalbuminuria (RR 2.64, 95%CI 2.13–3.27) for the risk of all-cause mortality, and also in microalbuminuria (RR 3.21, 95%CI
2.05–5.02) and macroalbuminuria (RR 11.63, 95%CI 5.68–23.83) for the risk of renal events. The magnitudes of relative risks
associated with low eGFR along with albuminuria were almost equal to multiplying each risk rate of low eGFR and
albuminuria. No significant factors were found by investigating potential sources of heterogeneity using subgroup analysis.
Conclusions: High albuminuria and low eGFR are relevant risk factors in diabetic patients. Albuminuria and low eGFR may
be independent of each other. To evaluate the effects of low eGFR, intervention, or race, appropriately designed studies are
needed.
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Introduction
The prevalence of diabetes is increasing globally, and manage-
ment of diabetic complications is particularly important. [1,2,3]
Diabetic nephropathy, resulting in end-stage renal events requir-
ing renal replacement therapy, is one of the most common
complications. Furthermore, in the course of diabetic nephropa-
thy, patients have higher rates of mortality from cardiovascular
disease. [4] Albuminuria is an early marker of diabetic nephrop-
athy, and previous reports described the association between
albuminuria and risks of adverse cardiovascular and kidney events.
[5,6] Albuminuria is often used as a surrogate marker for the risk
of fatal and non-fatal events in clinical trials of antihyperglycemic
medications or in antihypertensive therapy. [7,8,9] Similarly, low
eGFR, which is a common manifestation of progressed diabetic
nephropathy, has also been demonstrated to be an independent
risk factor for cardiovascular events and death. [10,11] Recent
evidence suggests that both high albuminuria and low eGFR are
independent risk factors for progressive kidney failure and
cardiovascular disease. [10] In addition, the magnitudes of risk
for progressive kidney failure, cardiovascular disease, and all-cause
mortality were different between studies, and the unevenness may
have been due to differences in study design or characteristics of
participants. It is important to clarify these problems to apply this
evidence to individuals.
To manage diabetic nephropathy, it is necessary to clarify the
precise magnitude of the risks for cardiovascular mortality, all-
cause mortality, and renal events according to the status of the
patient. These observations may be useful for the screening of
high-risk patients or considering interventions. Therefore, we
conducted a systematic review and meta-analysis of published
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studies on diabetic nephropathy to provide an accurate estimation
of the influence of albuminuria and low eGFR.
Methods
Data Sources and Searches
We conducted a systematic review of disease prognosis. A
systematic review of the available literature according to MOOSE
(meta-analysis of observational studies on epidemiology) guidelines
was conducted. MEDLINE (http://ovidsp.ovid.com/), EMBASE
(http://www.embase.com/), and CINHAL (http://www.
ebscohost.com/cinahl/) from 1950 until December 2010 were
searched, and the related literature were identified. Search
strategies consisted of medical subject headings and text words,
including all spellings of proteinuria, albuminuria, microalbumin-
uria, macroalbuminuria, and glomerular filtration rate combined
with cardiovascular diseases, mortality, renal events (Table 1), and
limited to cohort studies of diabetic patients. References from
identified studies were also screened manually.
Study Selection
Studies were included if they were cohort studies on diabetic
patients that estimated the relative risk (RR) and 95% confidence
intervals (CIs) of albuminuria or low eGFR on cardiovascular
mortality, all-cause mortality, or renal events, and the estimates
were derived from Cox proportional hazard models. The
definitions of albuminuria were pre-specified (Table 2). Studies
were included if they met the definitions of albuminuria in Table 2.
Cardiovascular mortality was defined as death from coronary
events and/or stroke, which may be on the basis of International
Classification of Diseases codes. Renal events were defined as renal
replacement therapy, renal transplantation, or loss of renal
function. Loss of renal function is defined as sustained eGFR or
creatinine clearance below 60 ml/min/1.73 m2 or less, halving of
eGFR, or doubling of serum creatinine.
Data Extraction and Quality Assessment
The literature search and screening were performed by two of
the authors (TT and MS). Authors independently judged the
contents of abstracts and full papers in duplicate using standard-
ized data collection form. Additional data were not collected from
authors of literature. To eliminate the potential influences of
specific disease, studies were excluded if their cohorts included
patients with specific complications. Studies were also excluded if
they reported estimates of influences without any information
about standard error, and if they did not yield an estimate that was
not adjusted at least by age.
Data Synthesis and Analysis
Random-effects model were used to obtain summary estimates
of RR and 95% CI. Summary estimates were obtained separately
according to the level of albuminuria (microalbuminuria, macro-
albuminuria, any level of albuminuria). If only subgroups of the
estimate were reported (e.g., by gender), these were pooled by
fixed-effects model as a within-study summary estimate. We also
investigated studies providing RR associated with low eGFR
according to the level of albuminuria. If the study population was
representative of a particular level of eGFR (e.g., eGFR .60), it
was handled as stratified. To evaluate the influences of albumin-
uria and low eGFR, compare the relative risks pooled by fixed-
effects model according to stratified category of albuminuria
(micro- and macroalbuminuria), low eGFR (, 60 mL/min/
Table 1. Search Strategies.
1: diabetes mellitus AND (proteinuria OR albuminuria OR microalbuminuria OR macroalbuminuria)
2: (diabetic nephropathy)
3: (kidney failure, chronic) OR (glomerular filtration rate)
4: (cardiovascular diseases) OR (cerebrovascular disorders)
5: mortality OR death
6: (cohort studies) OR (case-control studies)
(1 or 2) and (3 or 4 or 5) and 6
terms associated with Medical Subject Headings.
doi:10.1371/journal.pone.0071810.t001
Table 2. Definitions of Albuminuria.
Measurement Method Microalbuminuria Macroalbuminuria Any level of albuminuria
24 hour urine collection 30–300 mg/day or 20–200 mg/min .300 mg/day or .200 mg/min .30 mg/day or .20 mg/min
(proteinuria) N/A .0.3–0.5 g/day N/A
Spot urine albumin creatinine ratio 30–300 mg/g or 3.4–34 mg/mmol .300 mg/g or .34 mg/mmol .30 mg/g or .3.4 mg/mmol
(proteinuria) N/A .0.3–0.5 g/g N/A
Spot urine albumin concentration 3–30 mg/dl .30 mg/dl .3 mg/dl
(proteinuria) N/A .0.3–0.5 g/l N/A
Spot urine dipstick Specific microalbuminuria dipstick positive N/A N/A
Abbreviation: N/A, not available.
Based on Sarnak et al. [12].
doi:10.1371/journal.pone.0071810.t002
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1.73 m2) and normal eGFR ($ 60 mL/min/1.73 m2) regardless
of the reference category of eGFR. Heterogeneity between studies
was assessed using Cochran Q test and I2 value. Potential sources
of heterogeneity were examined by subgroup analysis comparing
summary estimates from subset of studies categorized by
characters of participants or study design. Univariate meta-
regression was used to compare the subgroups. Begg’s test [13]
and Egger’s test [14] were used to evaluate possible publication
bias (where P,0.05 was taken to indicate statistical significance).
To evaluate an influence of a single study, sensitivity analysis is
performed to examine the exclusion of any single study altered the
magnitude of relative risk or test for heterogeneity. All analyses
were performed using Stata (release 11.2; Stata Corporation,
College Station, TX). For all tests, a two-sided p-value below 0.05
was considered significant.
Results
Literature Search and Characteristics of Studies
The systematic database search yielded 6546 studies, of which
326 papers were reviewed in full (Figure 1). Finally, 31 studies that
fulfilled the criteria were included in the analysis, including
information for 148350 participants. The crude incidence rates
were 19.1 deaths from cardiovascular disease, 35.7 deaths, and
11.7 renal events (per 1000 person-years, respectively). The
process of study identification is shown in the flow chart, and
the study characteristics are listed in Table 3 and Table 4. Studies
consisted of four studies of type 1 diabetic patients, 23 studies of
type 2 diabetic patients, one study of type 1 and type 2 diabetic
patients, and 3 studies of unknown type of diabetic patients. The
study size was in the range of 146 to 94934, and the average
follow-up period was in the range of 3 to 19 years. Regarding
cardiovascular mortality, Asian population study was not included
according to the criteria. We pooled the risk of two studies [15,16]
reporting only subgroups of the estimate.
Micro- and macroalbuminuria were defined as risk factors in 25
studies. Any level of albuminuria (i.e., micro- or macroalbumin-
uria) was defined as a risk factor in 7 studies. In these studies,
various means of expression of albuminuria were adopted. The
magnitude of microalbuminuria was expressed as urinary albumin
excretion rate (n?12), urinary albumin-creatinine ratio on spot
urine samples (n?10), spot urinary albumin concentration (n?6),
qualitative test of albuminuria (n?2), or urinary protein excretion
rate (n?1). Almost all of the estimates were adjusted for multiple
risk factors including age. In one study [17], the estimate was not
adjusted for age because age was not a statistically significant risk.
Association of Albuminuria with Risk of Cardiovascular
Mortality
Microalbuminuria was associated with 1.76 (95% confidence
interval [CI] 1.38–2.25) times greater risk of cardiovascular
mortality as compared with normoalbuminuria (Figure 2), with
strong heterogeneity among studies (I2 = 66%, p=0.003 for
heterogeneity). We found no significant evidence of publication
bias. Subgroup analysis did not determine the suspected source of
heterogeneity (Figure S1). Age stratified analysis showed no trends
neither micro- nor macroalbuminuria (Figure S2). Macroalbu-
minuria was associated with about 2.96 (95%CI 2.44–3.60) times
greater risk of cardiovascular mortality compared with normoal-
Figure 1. Process for identification of eligible studies Abbreviation: N/A, not available.
doi:10.1371/journal.pone.0071810.g001
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Table 3. Characteristic of Studies Reporting on the Association between Albuminuria or low eGFR and Subsequent Risk of Adverse Outcomes.








Jager[15] 2010 Netherlands 173 48.0 100.0 CV mortality 16
O’Hare[16] 2010 US 94,934 98.0 87.0 All-cause mortality 25481
Grauslund[17] 2010 Denmark 389 55.0 N/A CV mortality All-cause mortality N/A 117
Molitch[18] 2010 US 1,439 52.5 N/A Renal events 89
Ninomiya[10] 2009 Multicountries 10,640 57.0 N/A CV mortality All-cause mortality Renal events 432 817 107
Groop[19] 2009 Finland 4,201 51.8 N/A All-cause mortality 291
de Boer[20] 2009 US 691 42.1 80.6 CV mortality All-cause mortality 169 378
Vlek[6] 2008 Netherlands 759 76.5 N/A CV mortality All-cause mortality 49 82
Luk[21] 2008 China 5,829 49.8 N/A Renal events 741
Tong[22] 2007 China 4,416 42.9 N/A All-cause mortality Renal events 110 221
Bruno[23] 2007 Italy 1,538 43.4 N/A CV mortality All-cause mortality 331 670
Roy[24] 2006 US 725 41.7 0.0 All-cause mortality 131
So[25] 2006 Hong Kong 4,421 43.2 N/A Renal events 212
Retnakaran[26] 2006 UK 5,032 59.0 81.0 Renal events 584
Xu[27] 2005 USA 1,953 37.6 N/Ae CV mortality All-cause mortality 223 627
Yuyun[28] 2003 UK 427 62.1 N/A All-cause mortality 56
Bruno[29] 2003 Italy 1,408 43.6 N/A Renal events 82
Jude[30] 2002 UK 340 66.5 66.8 CV mortality All-cause mortality 44 63
Ostgren[31] 2002 Sweden 400 50.5 N/A All-cause mortality 131
Stehouwer[32] 2002 Netherlands 328 61.6 N/A All-cause mortality 113
Gerstein[33] 2001 North and South
America and Europe
3,498 62.9 N/A All-cause mortality 431
de Grauw[34] 2001 Netherlands 262 39.0 N/A All-cause mortality 57
Florkowski[35] 2001 New Zealand 447 46.5 N/A All-cause mortality 187
Casiglia[36] 2000 Italy 683 50.2 N/A CV mortality 68
Valmadrid[37] 2000 US 840 45.0 N/A CV mortality All-cause mortality 364 529
Ha¨nninen[38] 1999 Finland 252 53.2 N/A All-cause mortality 21
Mattock[39] 1998 U.K. 146 56.2 100.0 CV mortality All-cause mortality 20 36




































































Rossing[41] 1996 Denmark 939 52.5 N/A CV mortality All-cause mortality 74 207
Gall[42] 1995 Denmark 328 61.5 N/A CV mortality 29






















of BP or HT
Stratification of eGFR
(ml/min/1.73m2 ) Level of Adjustmentd
64 T2DM N/A 67.8 139 83 Obs N/A NO N/A Age, sex, obesity, HT, TCHOL, TG, HDL, preexistent IHD,
current smoking
6.4 66.6 N/A N/A 75.3 139 74 Obs 60.7 YES $90, 89-60, 59-45, 44-30,
29-15
Age, sex, BMI, sBP, dBP, race, eGFR, comorbidity,
medication use
13 45.8 T1DM 30.0 68.0 N/A N/A Obs N/A NO N/A Age, sex, DM duration
19.3 27.1 T1DM 5.8 112.6 114 72 Trial 51.0 NO N/A Mean arterial pressure, ACE inhibitor use
4.3 66 T2DM 7 80.6 145 81 Trial 50.0 YES eGFR $90/60-89/,60 Age, sex, DM duration, HbA1c, BMI, sBP, history of currently
treated HT, logTG, HDL, LDL, ECG abnormalities, current
smoking, current drinking, history of macrovascular dis.
7 33.0 T1DM 23.2 75.9 134 80 Obs 28.9 NO N/A Age, duration of DM, HbA1c, eGFR, macrovascular disease
10 77.7 N/A N/A 76.0 138 69 Obs 25.3 YES 60 $, ,60 Age, sex, BMI, HT, DM duration, TCHO, hypoglycemic
medications, race, smoking, lipid-lowering medications,
prevalent cardiovascular disease, and prevalent congestive
heart failure.
4 59.7 N/A N/A 113.3 142 82 Obs 22.4 YES .60, ,60 Age, sex, sBP, dBP, HDL, LDL, vascular history, smoking
4.6 54.1 T2DM 6.2 91.0 133 76 Obs N/A YES N/A Age, sex, BMI, HT, DM duration, HbA1c, Retinopathy,
central obesity, hypertriglyceridemia
3.4 57.6 T2DM 5.3 110.3 135 77 Obs 9.3 YES N/A Renal failure: Age, waist circumference, sBP; All-cause
mortality: Age, sex, BMI
11 68.6 T2DM 10.8 N/A 155 78 Obs N/A YES .60, ,60 Age, sex, HT, HbA1c, apoB/apoA1, smoking, fibrinogen
3 29 T1DM 8.0 N/A N/A N/A Obs N/A YES N/A Age, BMI, dBP, diabetic retinopathy severity level, socio
economic status, macroangiopathy, heavy alcohol
consumption
3.3 57.6 T2DM 6.9 91.0 134 77 Obs 37.8 YES .90/60-89/30-39/15-29 Age, sex, DM duration, HbA1c, BMI, sBP, retinopathy, TG,
HDL, LDL, smoking, RAAS inhibition
15 52.4 T2DM 0 82.3 135 83 Trial N/A YES N/A Age, sex, ethnicity, Cr, smoking, waist, height, sBP,
retinopathy
8.8 57.1 T2DM 9.7 65.7 136 N/A Obs N/A YES N/A Age, sex, BMI, HT, DM duration, TG, HDL, LDL, study center,
percent of American Indian heritage, current alcohol
drinking, smoking, preexisting CVD
5 53.4 T1+T2DM 14.3 N/A N/A N/A Obs N/A YES N/A Age, sex, BMI, mean BP, duration of DM, TCHO, smoking,
type of DM, baseline cardiovascular history, rate of change
of albuminuria over 1 year

















































































of BP or HT
Stratification of eGFR
(ml/min/1.73m2 ) Level of Adjustmentd
5.3 60.8 T2DM 5.1 N/A 161 88 Obs N/A YES Age, sex, HT, DM duration, HbA1c, TCHO, sCr, race, pre-
existing IHD
5.9 69.6 T2DM 8.9 89.0 160 84 Obs N/A NO N/A Age and sex
9.0 53.8 T2DM 6.4 67.6 151 86 Obs N/A YES N/A Age, sex, BMI, sBP, DM duration, HbA1c, TCHOL, prior
cardiovascular disease
4.5 65.4 T2DM 11.4 73.5 142 80 Trial 50.5 YES N/A Age, sex, abdominal obesity, HT, DM duration,HbA1c,
dyslipidemia, diabetes status, smoking status, and sCr, use
of oral agents or insulin
6 66 T2DM 5 N/A 155 82 Obs N/A NO Age, sex, duration of DM
10 62.2 T2DM 9.6 N/A N/A N/A Obs N/A YES N/A Age, sex, DM duration, BMI, HbA1c, HT, PVD, smoking,
glucose, TCHOL, HDL, TG, cerebrovascular disease,
peripheral neuropathy, coronary artery disease, metformin,
sulphonylurea, combined oral, insulin
6 63.2 T2DM N/A N/A 156 90 Obs N/A YES mean -2S.D. .60 Age, coronary artery disease, sustained arterial
hypertension
12 67.9 T2DM 15.1 N/A 143 76 Obs N/A YES N/A Age, sex, glycemic control, insulin use, alcohol intake,
physical activity, history of CVD, intake of antihyptertensive
agents, and the presence and severity of diabetic
retinopathy
5 58 T2DM 6.0 N/A 145 90 Obs N/A NO N/A Age, sex, coronary heart disease
7 59 T2DM 5 N/A 144 84 Obs N/A NO N/A Age, sex, HbA1c, TCHO, preexistent coronary heart disease
4.8 63 T2DM 13 N/A 154 82 Obs N/A YES N/A Age, sex, DM duration, HbA1c, BMI, sBP, dBP, retiinopathy,
TCHO, HDL, TG, age at diagnosis, smoking, fasting glucose,
urea, loss of pinprick sensation, leg claudication, number of
abscent foot pulses, CHD, carebrovascular disease
9.2 39.6 T2DM 18.6 N/A 136 82 Obs N/A YES N/A Age, sex, HT, smoking, HbA1c, smoking, height, sCr, social
class, overt nephropthy
5.3 55.9 T2DM 6.3 N/A 151 86 Obs N/A YES N/A Age, HbA1c, sBP, coronary heart disease
6.1 66.2 T2DM 9.1 N/A 160 89 Obs N/A NO N/A Age, DM duration, retinopathy, lens opacity, intermittent
claudication
aEndpoints: CV mortality, cardiovascular mortality.
bType of DM: N/A, type of DM is not documented; T1DM, population with type 1 DM; T2DM, population with type 2 DM.
cStudy type: Obs, based on the cohort of observational study; Trial, based on the cohort of clinical trial.
dLevel of Adjustment: ACE, angiotensin converting enzyme; Apo, apolipoprotein; BMI, body mass index; CVD, cardiovascular disease; dBP, diastolic blood pressure; DM, diabetes mellitus; ECG, electrocardiogram; HbA1c,
glycosylated hemoglobin A1c; HDL, high-density lipoproteins; HT, hypertension; IHD, ischemic heart disease; LDL, low-density lipoproteins; PVD, peripheral vascular disease; RAAS, Renin-Angiotensin-Aldosterone System; sBP,
systolic blood pressure; sCr, serum creatinine TCHO, total cholesterol; TG, triglycerides;
eCohort of American Indians.







































































albuminuria eGFR categories Criteria of renal failure Criteria of CV mortality
Definition of CV
diseaseb
Jager [15] ACR .2.0 mg/mmol ICD code 390–459 Heart/Brain
O’Hare [16] ACR 30–299 mg/gCr $300 mg/gCr
Grauslund [17] spot 30–299 mg/L $300 mg/L ICD-9 codes 430.0–438.9
ICD-10 codes I20.0–I25.9, I60.0–
I60.9
Heart/Brain
Molitch [18] AER 30–300 mg/24 h .300 mg/24 h sustained eGFR,60
Ninomiya [10] ACR 30–300 mg/gCr .300 mg/gCr .90, 60–89, ,60 death as a result of kidney disease,
requirement for dialysis or
transplantation, or doubling of serum
creatinine to .200 mmol/L




Groop [19] AER 20–200 mg/min .200 mg/min
de Boer [20] ACR $30 mg/gCr $60, ,60 death from coronary heart
disease, myocardial infarction,
sudden cardiac death, or stroke
Heart/Brain
Vlek [6] ACR .3 mg/mmol .60, #60 Vascular death, Stroke,
Myocardial infarction
Heart/Brain
Luk [21] ACR 2.5–30 mg/mmol (women)
3.5–30 mg/mmol (men)
.30 mg/mmol ICD-9 code 250.4, 585, 586 ICD-9
procedure code 39.95 (hemodialysis),
54.98 (peritoneal dialysis)
Tong [22] ACR 3.5–25 mg/mmol $25 mg/mmol eGFR halving, eGFR ,15 ml/min/
1.73 m2, death as a result of renal causes
or need for dialysis
Bruno [23] AER 20–200 mg/min .200 mg/min $60, ,60 ICD code 390–459 Heart/Brain
Roy [24] AER 20–200 mg/min .200 mg/min
So [25] ACR 3.5–25 mg/mmol $25 mg/mmol .3.5 mg/mmol .90, 60–89, 30–59,
15–29
Reduction in eGFR by 50% or
progression to eGFR 15 ml/min/1.73 m2
(stage 5) or renal dialysis or death
secondary to renal causes
Retnakaran [26] spot 50–299 mg/L $300 mg/L Creatinine clearance #60 ml/min per
1.73 m2
Xu [27] ACR $30, ,300 mg/gCr $300 mg/gCr definite fatal MI, definite
sudden death due to CHD,
definite or possible fatal CHD,
definite or possible fatal stroke,
definite or possible fatal CHF,
and other fatal CVD
Heart/Brain
Yuyun [28] AER 30–300 mg/24 h .300 mg/24 h
Bruno [29] AER 20–200 ug/min .200 ug/min ESRD (need for dialysis) or chronic renal
failure
Jude [30] PER Urine protein $0.5 g/
24 h






































































albuminuria eGFR categories Criteria of renal failure Criteria of CV mortality
Definition of CV
diseaseb
Ostgren [31] qualitative Specific microalbumiuria
dipstick positive
Stehouwer [32] AER 30–299 mg/24 h $300 mg/24 h
Gerstein [33] ACR .2.0 mg/mmol
exclude dipstick–
positive proteinuria
de Grauw [34] spot 20–200 mg/L .200 mg/L
Florkowski [35] spot $50 mg/l
Casiglia [36] AER 30–300 mg/24 h .300 mg/24 h .60, #60 from the hospital of physicians’
files
Heart/Brain
Valmadrid [37] qualitative Agglutination inhibition
assay positive,and reagent
strip negative
Urine protein $0.3 g/L ICD9 codes 402, 404, 410–414,
428, 430–438
Heart/Brain
Ha¨nninen [38] AER $20 mg/min
Mattock [39] AER 20–200 mg/min UAER .200 mg/min from death certificates Heart
Beilin [40] spot 30–300 mg/L $300 mg/L ICD9 codes 390 to 458, 410 to
414
Heart/Brain
Rossing [41] AER 31–299 mg/24 h $300 mg/24 h from death certificate Heart/Brain
Gall [42] AER 30–299 mg/24 h AER $300 mg/24 h from death certificates Heart/Brain
Neil [43] spot 40–200 mg/L UAC .200 mg/L
aUrine measurement method: ACR, albumin creatinine ratio; AER, albumin excretion rate; PER, protein excretion rate; spot, spot urinary albumin concentration; qualitative, qualitative detection of albumin in urine.




























































buminuria, and there was no significant evidence of heterogeneity
among studies. These findings suggest that there is a dose-
dependent association between albuminuria and the risk of
cardiovascular mortality: the influence of macroalbuminuria was
significantly higher than that of microalbuminuria (p=0.026). In
the three studies for which information was available, any level of
albuminuria was associated with about 2.48 times (95%CI 1.57–
3.91) greater risk of cardiovascular mortality compared with
normoalbuminuria, without any evidence of heterogeneity in the
association.
Association of Albuminuria with Risk of All-cause
Mortality
Summary estimates of the influences of microalbuminuria and
macroalbuminuria on all-cause mortality were 1.60 (95%CI 1.42–
1.81) and 2.64 (95%CI 2.13–3.27), respectively (Figure 2): the
associations were heterogeneous among studies for both (I2 = 65%
and 84%, both p,0.001 for heterogeneity). There was some
evidence of publication bias in microalbuminuria and macroal-
buminuria (Egger’s test P?0.014 and P?0.015, respectively), which
may have overestimated the strength of the association. Subgroup
analysis did not determine the suspected source of heterogeneity.
As to the racial difference, relative risks were not significantly
different between Asians and non-Asians. A study in veterans
Figure 2. Risk ratio for the association between albuminuria and cardiovascular mortality, all-cause mortality, and renal events
compared with normoalbuminuria. Abbreviations: CI, confidence interval; RR, risk ratio.
doi:10.1371/journal.pone.0071810.g002
Figure 3. Risk ratio for the association of low eGFR with the risk of each outcome according to the presence of albuminuria,
compared with normal eGFR and normoalbuminuria. Albuminuria was defined as any level of albuminuria or pooled estimate of
microalbuminuria and macroalbuminuria. Abbreviations: normoalb, normoalbuminuria; alb, albuminuria.
doi:10.1371/journal.pone.0071810.g003
Impacts of Albuminuria and Low eGFR in Diabetes
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(O’Hare et al.) [18] yielded a lower risk of all-cause mortality (HR
1.34 [95%CI 1.30–1.38] for microalbuminuria, HR 1.73 [95%CI
1.63–1.84] for macroalbuminuria), but the source of heterogeneity
was not apparent (Figure S1). In age-stratified analysis, there was
no significant difference between younger and older age (Figure
S2). Sensitivity analysis excluding this study [18], with the highest
weight in this meta-analysis, showed a similar relative risk in
microalbuminuria (HR 1.65 [95% CI 1.46 – 1.87]) and macro-
albuminuria (HR 2.77 [95% CI 2.34 – 3.27]); the test for
heterogeneity was insignificant in microalbuminuria (I2?41.0%,
P?0.06), and was still significant for macroalbuminuria (I2?51.1%,
P?0.02). The summary estimate of the influence of any level of
albuminuria for the risk of all-cause mortality was 1.69 (95%CI
1.48–1.93).
Association of Albuminuria with Risk of Renal Events
Summary estimates of the influences of microalbuminuria and
macroalbuminuria on renal events were 3.21 (95%CI 2.05–5.02)
and 11.63 (95%CI 5.68–23.83), respectively (Figure 2): the risk
estimates of micro- and macroalbuminuria were diverse across
studies (I2 = 76% and 92%, p=0.02 and p,0.001 for heteroge-
neity). We found no significant evidence of publication bias.
Subgroup analysis did not show any significant differences
between characteristics of participants or study design (Figure
S1). Asians have almost the same risk for renal events as non-
Asians in both micro- and macroalbuminuria. Age stratified
analysis showed no trends in microalbuminuric or macroalbumi-
nuric patients (Figure S2). One study evaluating the influences of
any level of albuminuria showed the same trend.
Combined Impacts of Low eGFR on Albuminuria
A few studies [6,10,19,20] evaluated the combined influence of
low eGFR on albuminuria in terms of the risk for the outcomes. As
compared to those with normoalbuminuria, the risk of cardiovas-
cular mortality tended to increase by 1.70-fold (95%CI 0.83–3.49)
in subjects with normoalbuminuria and eGFR of ,60 mL/min/
1.73 m2 (Figure 3). Similarly, the presence of albuminuria was
significantly associated with 2.46-fold (95%CI 1.96–3.07) in-
creased risk of cardiovascular mortality. Furthermore, subjects
with both albuminuria and eGFR ,60 mL/min/1.73 m2 were at
4.20 times (95%CI 3.11–5.68) higher risk of cardiovascular
mortality compared to those with neither of these risk factors.
Discussion
This study explored the influences of albuminuria and low
eGFR on cardiovascular mortality, all-cause mortality, and renal
events in diabetic patients using meta-analysis methods with
148350 cases. Microalbuminuria and macroalbuminuria are
significant risk factors for each outcome. Similar to the influences
of albuminuria, low eGFR also increased the risk of each adverse
outcome.
This meta-analysis suggested that low eGFR and albuminuria
may be independent risk factors for cardiovascular mortality, all-
cause mortality, and renal events. Recent published new CKD
staging from Kidney Disease: Improving Global Outcomes
(KDIGO) was defined by these two factors, eGFR and albumin-
uria. [44,45] However, conventional staging of diabetic nephrop-
athy was classified only by degree of albuminuria. [46] Many
reports and meta-analysis indicated albuminuria as one of the
main risk factors for cardiovascular mortality and all-cause
mortality in diabetic patients. [47] Although the number of
reports was limited, some indicated the influences of low eGFR on
the risk of each outcome in diabetic nephropathy. [10,19,20]
However, other reports concluded that low eGFR was not always
a significant risk factor for these outcomes. [6,25] Thus, the
influences of albuminuria and low eGFR are not consistent among
studies adjusted for each other. Further large prospective studies
are needed to clarify the independent influences of albuminuria
and low eGFR on the three outcomes in diabetic nephropathy.
The interaction between eGFR and albuminuria may be
important in considering the possibility of albuminuria and low
eGFR as independent risk factors for the three outcomes. Previous
meta-analyses of general and high-risk cohorts indicated no
interaction between eGFR and albuminuria on the risks of
cardiovascular mortality, all-cause mortality, and renal events.
[48,49] Similarly, in our results of diabetic nephropathy consisting
of 4 data or less, stratified analysis demonstrated that the
magnitudes of relative risks of these events with low eGFR and
albuminuria were almost equivalent to those obtained by
multiplying each risk rate of low eGFR and albuminuria. These
results suggested that there is no interaction between eGFR and
albuminuria in each adverse outcome. In our meta-analysis, only
two studies evaluated the interaction between eGFR and
albuminuria. [10,25] One of these studies that included stratified
analysis indicated that increasing risk of cardiovascular mortality
and all-cause mortality in low eGFR were significantly higher in
patients with macroalbuminuria but not those with normoalbu-
minuria. [25] Moreover, in a previous meta-analysis, one of eight
general and high-risk cohorts showed significant interaction
between eGFR and albuminuria for the risk of ESRD. [49] Based
on these studies, the significance of the interaction between eGFR
and albuminuria is still variable. Detailed analysis of cohort
studies, including an unusual case of diabetic nephropathy, such as
low eGFR with normoalbuminuria and high GFR with macro-
albuminuria, are needed to resolve the precise interaction of them.
There was heterogeneity among studies for cardiovascular
mortality, all-cause mortality, and renal events in the presence of
microalbuminuria or macroalbuminuria. There are some possible
causes of the heterogeneity in this study. One of the possible
reasons is a large cohort with different results from the others.
Another possible reason is the diversity of study design. A large
study with an exceptional setting [18] may lead to heterogeneity of
the outcome. The report by O’Hare et al. had the highest weight
in this meta-analysis, and its relative risk was even lower than the
pooled risk of all-cause mortality. [18] Therefore, this large cohort
study of veterans should have some different setting from other
studies. The multiplicity of study design is an unavoidable
limitation of meta-analyses, which is another possible reason of
heterogeneity. The entry criteria, treatment, or adjustment for
confounders were different between studies, and the different
settings may affect results to uneven extents. Although some other
factors, such as blood pressure control or use of ACE inhibitors for
renal events, are possible factors for heterogeneity, these factors
were not fully evaluated in the studies included in this analysis.
[50,51] Based on these results, standardization of study design is
needed, including treatment strategy or adjustment of confound-
ers.
As diabetes is a common disease with high risk of macrovascular
and microvascular complications, we focused on diabetic patients.
In this sense, we excluded patients without diabetes from this
study. Due to this restriction of subjects, our study precisely
compared the outcomes of the studies of diabetic cohorts. On the
other hand, out study was not able to describe the risk of patients
with diabetes compared to those without diabetes.
The strength of this study is the listing of all studies allowing
readers to see the inconsistency across cohorts. The limitations of
this study should also be noted. First, the numbers of studies
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regarding the associations between low eGFR and cardiovascular
mortality, all-cause mortality, and renal events were small.
Although low eGFR was considered as a risk factor for
cardiovascular events according to the guidelines developed by
KDIGO in 2002, there were few studies from this viewpoint prior
to this time. [44] Second, each study had its own definition of
normal eGFR as the reference category for multivariate analysis.
Some studies [10,19] defined normal eGFR as .90 mL/min/
1.73 m2, while others [6,20] used a definition of .60 mL/min/
1.73 m2. The difference in definition may have affected the
magnitude of pooled risk ratio for each outcome. Third, there
were differences in measurement and expression of albuminuria,
such as daily excretion of albumin, or the ratio of urinary albumin
to creatinine. Moreover, measurement of urinary albumin was still
not standardized. [52,53,54] A standardized method for measure-
ment of albuminuria is essential for comparing data across studies.
Furthermore, collection of urine was also not standardized. Spot
urine sample collection in the morning or daily collection of urine
would lead to different magnitudes of risk ratio., [55] With regard
to expression of urinary albumin, some guidelines [56,57,58] use
albumin/creatinine ratio. However, other expressions were also
used in different studies, such as 24-h excretion or concentration of
urinary albumin. Fourth, there may be problems associated with
reporting bias, especially for renal events. Some studies measuring
serum creatinine at baseline did not report renal outcome. The
outcome reporting bias may have increased the influence of renal
outcome, which is a very large risk ratio compared with
cardiovascular or all-cause mortality. Fifth, the numbers of studies
reporting the influence of low eGFR were small. Our search
strategy limited objects as ‘‘diabetes with albuminuria/protein-
uria’’ or ‘‘diabetic nephropathy.’’ Therefore, studies of diabetic
patients with low eGFR may not have been included in our
systematic review due to our search strategy. Sixth, making the
best use of information about study design or baseline character-
istics, the threshold of study size was not used as a limitation in
study selection. These selection criteria resulted in more than half
of the selected studies consisted of less than 1000 participants.
With regard to the effects of albuminuria and eGFR in diabetic
patients, the Chronic Kidney Disease Prognosis Consortium
(CKDPC) reported a precise estimate of risk [59]. In addition,
our study provided further information showing the inconsistency
of study design or subgroup analysis, and presented pooled risk
ratio by category of albuminuria and low eGFR for use in clinical
care. Moreover, information about intervention or race (except
Caucasian) is limited in both the report of CKDPC and this
systematic review.
In summary, we conducted a systematic review and meta-
analysis, including 148350 cases, and described the impacts of
albuminuria and low eGFR on the risks of cardiovascular
mortality, all-cause mortality, and renal events. Micro- and
macroalbuminuria were significant risk factors for all three
outcomes, and low eGFR and albuminuria may be independent
risk factors. There was less evidence exploring the influences of low
eGFR as independent risk factor on the outcomes. To evaluate the
effects of low eGFR, intervention, or race, including Asian
subjects, individual patient data meta-analysis or long-term
prospective studies based on individual patient data are needed.
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